Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing (Q34288940)

1 August 2017

1 reference

title

Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing (English)

1 reference

1 August 2017

DeNardo GL

1

1 reference

1 August 2017

Juweid ME

2

1 reference

1 August 2017

White CA

3

1 reference

1 August 2017

Wiseman GA

4

1 reference

1 August 2017

DeNardo SJ

5

1 reference

1 August 2017

language of work or name

1 reference

1 July 2001

1 reference

Critical Reviews in Oncology Hematology

1 August 2017

published in

1 reference

1 August 2017

volume

39

1 reference

1 August 2017

issue

1-2

1 reference

1 August 2017

page(s)

203-218

1 reference

Internal dosimetry in the use of radiopharmaceuticals in therapy--science at a crossroads?

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Dosimetry and treatment planning for 90Y-labeled antiferritin in hepatoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

MABDOS: a generalized program for internal radionuclide dosimetry

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Quantitative SPECT of uptake of monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Development of a method to measure kinetics of radiolabelled monoclonal antibody in human tumour with applications to microdosimetry: positron emission tomography studies of iodine-124 labelled 3F8 monoclonal antibody in glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

A critical analysis of the quantitative I131 therapy of thyrotoxicosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

The value of a tracer dose in predicting the kinetics of therapeutic doses of131I in thyrotoxicosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Monte Carlo-assisted voxel source kernel method (MAVSK) for internal beta dosimetry

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Reproducibility of operator processing for radiation dosimetry

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131I-Lym-1 as a model

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Comparison of bone marrow dosimetry and toxic effect of high dose 131I-labeled monoclonal antibodies administered to man

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Haematological effects of radioimmunotherapy in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Calculation of radioactive iodine beta radiation dose to the bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Can clinical data help to screen patients with lymphoma for MR imaging of bone marrow?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Therapy of peritoneal carcinomatosis of human colon cancer xenografts with yttrium 90-labeled anti-carcinoembryonic antigen antibody ZCE025.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Comparison of five bifunctional chelate techniques for 90Y-labeled monoclonal antibody CO17-1A

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Comparison of 131I- and 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

The beginnings of radioiodine therapy of metastatic thyroid carcinoma: a memoir of Samuel M. Seidlin, M. D. (1895-1955) and his celebrated patient

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Blood radiation dose during radioiodine therapy of metastatic thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

A Monte-Carlo program converting activity distributions to absorbed dose distributions in a radionuclide treatment planning system

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Evaluating changes in stable chromosomal translocation frequency in patients receiving radioimmunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

Accelerated titration designs for phase I clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900109-3

7 January 2021

10.1016/S1040-8428(01)00109-3

Identifiers

DOI

1 reference

release_tnmschtkkvg2xdvjrsvsixc74q

1 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tnmschtkkvg2xdvjrsvsixc74q

24 November 2022

mapped directly with Wikidata item

1 reference